These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 26655727)

  • 21. [Vaccination with three HIV-1 cross neutralizing epitopes fused to HBV S antigen could induce robust antibody immune response in mice].
    Li XR; Chen H; Wang W; Deng Y; Qi XR; Gao YY; Meng X; Tan WJ; Ruan L
    Bing Du Xue Bao; 2008 Jul; 24(4):260-7. PubMed ID: 18780627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Construction of recombinant targeting immunogens incorporating an HIV-1 neutralizing epitope into sites of differing conformational constraint.
    Ho J; MacDonald KS; Barber BH
    Vaccine; 2002 Jan; 20(7-8):1169-80. PubMed ID: 11803079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library.
    Zhou M; Meyer T; Koch S; Koch J; von Briesen H; Benito JM; Soriano V; Haberl A; Bickel M; Dübel S; Hust M; Dietrich U
    Eur J Immunol; 2013 Feb; 43(2):499-509. PubMed ID: 23180650
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.
    Maeso R; Huarte N; Julien JP; Kunert R; Pai EF; Nieva JL
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):863-76. PubMed ID: 21142698
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A mimotope peptide-based vaccine against Schistosoma mansoni: synthesis and characterization.
    Arnon R; Tarrab-Hazdai R; Steward M
    Immunology; 2000 Dec; 101(4):555-62. PubMed ID: 11122460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Variable epitope libraries: new vaccine immunogens capable of inducing broad human immunodeficiency virus type 1-neutralizing antibody response.
    Charles-Niño C; Pedroza-Roldan C; Viveros M; Gevorkian G; Manoutcharian K
    Vaccine; 2011 Jul; 29(32):5313-21. PubMed ID: 21600948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunogenicity of neutralizing epitopes on multiple-epitope vaccines against HIV-1.
    Lu Y; Xiao Y; Ding J; Dierich M; Chen YH
    Int Arch Allergy Immunol; 2000 Jan; 121(1):80-4. PubMed ID: 10686512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies.
    Quakkelaar ED; van Alphen FP; Boeser-Nunnink BD; van Nuenen AC; Pantophlet R; Schuitemaker H
    J Virol; 2007 Aug; 81(16):8533-42. PubMed ID: 17522228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb.
    McGaughey GB; Citron M; Danzeisen RC; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller M; Shiver J; Bogusky MJ
    Biochemistry; 2003 Mar; 42(11):3214-23. PubMed ID: 12641452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An immunogen containing four tandem 10E8 epitope repeats with exposed key residues induces antibodies that neutralize HIV-1 and activates an ADCC reporter gene.
    Sun Z; Zhu Y; Wang Q; Ye L; Dai Y; Su S; Yu F; Ying T; Yang C; Jiang S; Lu L
    Emerg Microbes Infect; 2016 Jun; 5(6):e65. PubMed ID: 27329850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice.
    Zhou M; Kostoula I; Brill B; Panou E; Sakarellos-Daitsiotis M; Dietrich U
    Vaccine; 2012 Mar; 30(11):1911-6. PubMed ID: 22269872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eliciting neutralizing antibodies against the membrane proximal external region of HIV-1 Env by chimeric live attenuated influenza A virus vaccines.
    Zang Y; Du D; Li N; Su W; Liu X; Zhang Y; Nie J; Wang Y; Kong W; Jiang C
    Vaccine; 2015 Jul; 33(32):3859-64. PubMed ID: 26126669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
    Zwick MB; Jensen R; Church S; Wang M; Stiegler G; Kunert R; Katinger H; Burton DR
    J Virol; 2005 Jan; 79(2):1252-61. PubMed ID: 15613352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel approaches in polyepitope T-cell vaccine development against HIV-1.
    Karpenko LI; Bazhan SI; Antonets DV; Belyakov IM
    Expert Rev Vaccines; 2014 Jan; 13(1):155-73. PubMed ID: 24308576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120.
    Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y
    Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenicity of recombinant influenza virus haemagglutinin carrying peptides from the envelope protein of human immunodeficiency virus type 1.
    Kalyan NK; Lee SG; Wilhelm J; Pisano MR; Hum WT; Hsiao CL; Davis AR; Eichberg JW; Robert-Guroff M; Hung PP
    Vaccine; 1994 Jun; 12(8):753-60. PubMed ID: 7522383
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitope.
    Menendez A; Chow KC; Pan OC; Scott JK
    J Mol Biol; 2004 Apr; 338(2):311-27. PubMed ID: 15066434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.
    Hessell AJ; McBurney S; Pandey S; Sutton W; Liu L; Li L; Totrov M; Zolla-Pazner S; Haigwood NL; Gorny MK
    Vaccine; 2016 May; 34(24):2713-21. PubMed ID: 27102818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of monoclonal antibody with predefined ELNKWA epitope specificity by epitope vaccine.
    Xiao Y; Dong XN; Chen YH
    Hybridoma; 2000 Aug; 19(4):347-50. PubMed ID: 11001409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.